NEW YORK (GenomeWeb News) – Investment bank Goldman Sachs has reinstated coverage of Illumina, giving it a Neutral rating and a 12-month price target on its stock of $48.

The bank suspended coverage of Illumina shortly after Roche launched its hostile bid for the San Diego firm. Goldman Sachs was an advisor to Illumina on the proposed deal, which ended when Roche abandoned its pursuit last month.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.